Article: Rituximab and concomitant leflunomide for the treatment of rheumatoid arthritis

Rituximab has only been approved in combination with methotrexate for the treatment of rheumatoid arthritis. As some patients have intolerance to methotrexate, alternative co-therapies are needed. This method involved retrospective analysis of ten patients treated with a combination of rituximab and leflunomide. Primary outcome measures were the DAS28 response at month 6 and the time to relapse. The median initial DAS 28 of 5.7 (3.2-7.2) was reduced to 3.5 (1.9-6.1) at month 6. 70% of the patients achieved a good or moderate response, whereas 30% showed no response. Two patients had to stop leflunomide due to adverse effects. Two patients had to reduce the leflunomide dose to 10 mg/day. 5/8 patients experienced a relapse after a median of 10 (6-30) months and were successfully re-treated with rituximab. This small case series suggests that leflunomide might offer an alternative DMARD combination option for the treatment of RA with rituximab.

Citing Articles

Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study).

Behrens F, Koehm M, Rossmanith T, Alten R, Aringer M, Backhaus M Rheumatology (Oxford). 2021; 60(11):5318-5328.

PMID: 33738492 PMC: 8566251. DOI: 10.1093/rheumatology/keab153.

Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis.

Jones P, White D Open Access Rheumatol. 2010; 2:53-71.

PMID: 27789998 PMC: 5074775. DOI: 10.2147/OARRR.S9448.

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis.

Emery P, Sebba A, Huizinga T Ann Rheum Dis. 2013; 72(12):1897-904.

PMID: 23918035 PMC: 3841743. DOI: 10.1136/annrheumdis-2013-203485.

[Non-TNF biologicals in the therapeutic strategy for rheumatoid arthritis].

Wollenhaupt J, Kruger K Z Rheumatol. 2010; 69(7):618-25.

PMID: 20703488 DOI: 10.1007/s00393-009-0532-5.

References

1.

Finckh A, Dehler S, Gabay C . The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. Ann Rheum Dis. 2008; 68(1):33-9. DOI: 10.1136/ard.2007.085696. View

2.

van der Heijde D, van t Hof M, van Riel P, Theunisse L, Lubberts E, van Leeuwen M . Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990; 49(11):916-20. PMC: 1004262. DOI: 10.1136/ard.49.11.916. View

3.

Kalden J, Schattenkirchner M, Sorensen H, Emery P, Deighton C, Rozman B . The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study. Arthritis Rheum. 2003; 48(6):1513-20. DOI: 10.1002/art.11015. View

4.

Arnett F, Edworthy S, Bloch D, McShane D, Fries J, Cooper N . The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31(3):315-24. DOI: 10.1002/art.1780310302. View

5.

Keystone E, Fleischmann R, Emery P, Furst D, van Vollenhoven R, Bathon J . Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007; 56(12):3896-908. DOI: 10.1002/art.23059. View

6.

Edwards J, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close D . Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004; 350(25):2572-81. DOI: 10.1056/NEJMoa032534. View

7.

van Gestel A, Haagsma C, van Riel P . Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998; 41(10):1845-50. DOI: 10.1002/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K. View

8.

Owczarczyk K, Hellmann M, Fliedner G, Rohrs T, Maizus K, Passon D . Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate. Ann Rheum Dis. 2008; 67(11):1648-9. DOI: 10.1136/ard.2007.087023. View

9.

Cohen S, Emery P, Greenwald M, Dougados M, Furie R, Genovese M . Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006; 54(9):2793-806. DOI: 10.1002/art.22025. View

10.

Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A . The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006; 54(5):1390-400. DOI: 10.1002/art.21778. View

Rituximab and Concomitant Leflunomide for the Treatment of Rheumatoid Arthritis